4.4 Review

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?

期刊

RHEUMATOLOGY INTERNATIONAL
卷 41, 期 8, 页码 1515-1521

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-021-04896-2

关键词

Coronavirus disease 2019; Severe acute respiratory syndrome— coronavirus 2; Eosinophilic granulomatosis with polyangiitis; Churg strauss syndrome

向作者/读者索取更多资源

COVID-19 and eosinophilic granulomatosis with polyangiitis (EGPA) can present similarly in clinical and imaging findings, making it a diagnostic challenge to differentiate between the two during the current pandemic, especially when other EGPA symptoms are overlooked. This study reviewed cases involving EGPA patients with COVID-19, as well as patients initially suspected to have COVID-19 but eventually diagnosed with EGPA, providing insights into navigating the diagnostic challenge presented by EGPA/COVID-19 during the pandemic.
Coronavirus disease 2019 (COVID-19) and eosinophilic granulomatosis with polyangiitis (EGPA) share similarities in clinical, imaging findings and may present with respiratory distress. Differentiating a new-onset EGPA from COVID-19 during the current pandemic is a diagnostic challenge, particularly if other EGPA symptoms are overlooked. Here in this study we reviewed the literature regarding EGPA patients with COVID-19 and patients who diagnosed with EGPA or suffered an EGPA flare mimicking COVID-19. We conducted a literature survey in PUBMED database using meshed keywords COVID-19 and EGPA, COVID-19 and eosinophilic granulomatosis with polyangiitis, COVID-19 and Churg Strauss Syndrome, to reveal previously reported cases involving EGPA patients who had COVID-19 infection, patients who suspected to have COVID-19 but eventually diagnosed with EGPA and patients with a known diagnosis of EGPA who suffered a flare but a COVID-19 infection was suspected initially. A total of 11 cases (6 literature cases, 5 cases from our clinic) were included in our study. Seven (63.6%) of the cases were defined as COVID-19 mimicker and 4 (36.4%) were EGPA with COVID-19. All of the cases in EGPA with COVID-19 group had a history of asthma. All of them had a positive PCR result and ground-glass opacities in thorax CT. In COVID-19 mimicker group, six (85.7%) patients had a history of asthma and other EGPA features that were observed were eosinophilia in 6 (85.7%). Our study provided clues regarding the EGPA/COVID-19 diagnostic challenge which may be useful in the current pandemic. Since none of the findings in COVID-19 are disease-specific, other conditions like EGPA should not be overlooked particularly in PCR negative patients and clinical, laboratory and imaging findings should be interpreted carefully. Furthermore, we did not observe poor outcomes in EGPA patients who had COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据